睿知中国医院研究地图
候选清单

长春吉林大学

吉林大学第一医院

First Hospital of Jilin University

在本站收录的 53 种疾病中,这家医院列在其中 37 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

官方链接已于 2026-11-08 打开核对。

联系这家医院

吉林大学第一医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma3 篇牵头论文
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma5 篇牵头论文
  3. 肝细胞癌Hepatocellular carcinoma76 篇牵头论文牵头 1 项开放试验
  4. 胃癌Stomach cancer41 篇牵头论文牵头 7 项开放试验
  5. 肝母细胞瘤Hepatoblastoma1 篇牵头论文
  6. 视网膜母细胞瘤Retinoblastoma3 篇牵头论文
  7. 脊索瘤Chordoma0 篇牵头论文
  8. 骨肉瘤Osteosarcoma17 篇牵头论文
  9. 胃肠道间质瘤Gastrointestinal stromal tumour0 篇牵头论文
  10. 神经母细胞瘤Neuroblastoma7 篇牵头论文
  11. 尤文肉瘤Ewing sarcoma2 篇牵头论文
  12. 多发性骨髓瘤Multiple myeloma17 篇牵头论文牵头 4 项开放试验
  13. B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia0 篇牵头论文
  14. 再生障碍性贫血Aplastic anaemia2 篇牵头论文
  15. 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis4 篇牵头论文
  16. 血友病 AHaemophilia A0 篇牵头论文
  17. 非典型溶血性尿毒症综合征Atypical haemolytic uraemic syndrome2 篇牵头论文
  18. 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura1 篇牵头论文
  19. 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder11 篇牵头论文
  20. 重症肌无力Myasthenia gravis1 篇牵头论文
  21. 烟雾病Moyamoya disease4 篇牵头论文
  22. 肝豆状核变性Wilson disease2 篇牵头论文
  23. 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis5 篇牵头论文
  24. 大动脉炎Takayasu arteritis2 篇牵头论文
  25. 特发性肺纤维化Idiopathic pulmonary fibrosis1 篇牵头论文
  26. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis2 篇牵头论文
  27. 脊髓性肌萎缩症Spinal muscular atrophy0 篇牵头论文
  28. 法布雷病Fabry disease1 篇牵头论文
  29. 杜氏肌营养不良Duchenne muscular dystrophy0 篇牵头论文
  30. 白塞病Behçet disease3 篇牵头论文
  31. Alport 综合征Alport syndrome0 篇牵头论文
  32. IgA 肾病IgA nephropathy7 篇牵头论文牵头 1 项开放试验
  33. 戈谢病Gaucher disease1 篇牵头论文
  34. 成骨不全症Osteogenesis imperfecta0 篇牵头论文
  35. 原发性胆汁性胆管炎Primary biliary cholangitis11 篇牵头论文
  36. 原发性硬化性胆管炎Primary sclerosing cholangitis1 篇牵头论文
  37. 家族性腺瘤性息肉病Familial adenomatous polyposis0 篇牵头论文

未列出的收录疾病:β 地中海贫血、范可尼贫血、IgG4相关性疾病、胆道闭锁、肝包虫病、肺淋巴管平滑肌瘤病、庞贝病、尼曼-匹克病 C 型、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.1%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 0020232024: 0020242025: 112025

长春有 3 家医院列在鼻咽癌下全国有 183 家医院列在鼻咽癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的鼻咽癌开放试验。

这些数字背后的记录
研究主题影像与人工智能放疗技术副作用与生活质量
论文中的科室放疗科
牵头的论文3
  1. Continual source-free active domain adaptation for nasopharyngeal carcinoma tumor segmentation across multiple hospitals.2025Neural networks : the official journal of the International Neural Network Society
  2. Research progress on mechanism and imaging of temporal lobe injury induced by radiotherapy for head and neck cancer.2022European radiology
  3. A network meta-analysis for efficacies and toxicities of different therapeutic regimens in the treatment of advanced nasopharyngeal carcinoma.2021European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC状态不明NCT02915432研究中心I/II期2016-12 启动
PubMed 以外找到的论文(未计入)5
  1. Spontaneous resolution of laryngeal contact granuloma following radiotherapy for nasopharyngeal carcinoma: A case report2025Asian Journal of Surgery论文
  2. Synthesis of gold nanoparticles using Ginkgo biloba leaf extract and its in vitro anticancer effects on nasopharyngeal carcinoma cells2024Alexandria Engineering Journal论文
  3. Additional file 1 of Comparing the efficacy and safety of cisplatin and other platinum-based chemotherapies in locally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis2022Figshare综述
  4. Long intergenic non-protein coding RNA 02570 promotes nasopharyngeal carcinoma progression by adsorbing microRNA miR-4649-3p thereby upregulating both sterol regulatory element binding protein 1, and fatty acid synthase2021Figshare数据集
  5. MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC2021Journal of Thoracic Oncology会议摘要

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.2%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 0020242025: 332025

长春有 3 家医院列在食管鳞状细胞癌下全国有 192 家医院列在食管鳞状细胞癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
    分期
    III期
    开始
    2025-03
    登记号
    NCT06644781

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 28 家列出的医院为研究中心临沂、北京、南宁、厦门、合肥、哈尔滨、天津、安阳、成都、扬州、新乡、杭州、武汉、汕头、沈阳、洛阳、济南、济宁、福州、郑州、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题免疫治疗手术影像与人工智能
牵头的论文5
  1. FSCN1 regulates TGF-β signalling to promote esophageal squamous cell carcinoma metastasis via stabilizing THBS1 mRNA.2025Communications biology免费全文
  2. FBXO10 inhibits ferroptosis and promotes the progression of esophageal squamous cell carcinoma by post-translational mediation of ACSL4 degradation.2025Journal of molecular histology
  3. A nomogram to predict long-term survival after resection for esophageal cancer: An observational study in northeast China.2025Surgery
  4. Molecular profiles of different PD-L1 expression in patients with esophageal squamous cell carcinoma.2023Cancer biology & therapy免费全文
  5. Case Report: First-Line Immunotherapy for Esophageal Squamous Carcinoma Combined With Hypopharyngeal Squamous Carcinoma Yields Sustained Survival Benefit.2022Frontiers in immunology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)7
  1. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)正在招募NCT06644781研究中心III期2025-03 启动
  2. A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma已完成NCT04540211研究中心III期2020-10 启动
  3. A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma已完成NCT03430843研究中心III期2018-01 启动
  4. Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell Carcinoma状态不明NCT03817567研究中心I/II期2018-07 启动
  5. Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study已完成NCT03933449研究中心III期2016-12 启动
  6. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC状态不明NCT02915432研究中心I/II期2016-12 启动
  7. Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma状态不明NCT01232374研究中心II期2010-09 启动
PubMed 以外找到的论文(未计入)15
  1. Abstract 1945: High-sensitive gastrointestinal cancers early detection by cell-free DNA targeted methylation sequencing with an innovative modeling approach2025Cancer Research会议摘要
  2. Combining the Albumin-to-fibrinogen ratio and pathologic factors predicts survival in surgically treated patients with esophageal squamous cell carcinoma2024ONCOLOGIE论文
  3. Efficacy and safety analysis on the combination of camrelizumab with nab-paclitaxel and cisplatin-based chemotherapy in first-line treatment of advanced or metastatic esophageal squamous cell carcinoma.2024Journal of Clinical Oncology会议摘要
  4. Additional file 1 of Hypoxia-induced TMTC3 expression in esophageal squamous cell carcinoma potentiates tumor angiogenesis through Rho GTPase/STAT3/VEGFA pathway2023Figshare数据集
  5. Effectiveness and safety of camrelizumab in advanced esophageal cancer: A prospective multicenter observational cohort studies (ESCORT-RWS).2023Journal of Clinical Oncology会议摘要
  6. Safety and feasibility of neoadjuvant immunotherapy combined with chemotherapy for resectable locally advanced esophageal squamous cell carcinoma2023Research Square预印本
  7. Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma2022Figshare数据集
  8. Additional file 1 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figshare数据集
  9. Additional file 1 of PABPC1-induced stabilization of IFI27 mRNA promotes angiogenesis and malignant progression in esophageal squamous cell carcinoma through exosomal miRNA-21-5p2022Figshare数据集
  10. Additional file 2 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figshare数据集
  11. Additional file 4 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figshare数据集
  12. Additional file 5 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figshare数据集
  13. Additional file 7 of Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma2022Figshare数据集
  14. Downregulation of long noncoding RNA breast cancer anti-estrogen resistance 4 inhibits cell proliferation, invasion, and migration in esophageal squamous cell carcinoma by regulating the microRNA-181c-5p/LIM and SH3 protein 1 axis2022Figshare数据集
  15. [Retracted] MicroRNA‑338‑3p suppresses tumor growth of esophageal squamous cell carcinoma in vitro and in vivo2021Molecular Medicine Reports论文

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 76 篇,占 0.5%。

牵头论文
76
2021–2025 年
牵头试验
3
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
5
由其他机构牵头
每年牵头的论文数
2021: 9920212022: 141420222023: 181820232024: 262620242025: 882025

长春有 4 家医院列在肝细胞癌下全国有 194 家医院列在肝细胞癌下

这家医院参与的开放试验 6

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 即将招募
    Hybrid Deep Learning Integrating Multimodal CEUS and Enhanced MRI to Optimize Early-Stage HCC Treatment Decisions
    分期
    未注明
    开始
    2026-04
    登记号
    NCT07582419

    年龄 18 岁 至 85 岁(登记的条件)

    牵头:吉林大学第一医院长春

  2. 正在招募
    A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
    分期
    I/II期
    开始
    2026-05
    登记号
    NCT07547553

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、天津、广州、沈阳、福州、蚌埠、郑州、长春

  3. 正在招募
    Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
    分期
    I期
    开始
    2025-11
    登记号
    NCT07176650

    年龄 18 岁 至 65 岁(登记的条件)

    牵头方不是列出的医院;另有 27 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、天津、广州、成都、杭州、武汉、沈阳、海口、石家庄、福州、蚌埠、西安、郑州、长春

  4. 正在招募
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    分期
    II期
    开始
    2025-06
    登记号
    NCT07327034

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 39 家列出的医院为研究中心上海、北京、南京、南宁、南昌、南通、合肥、天津、广州、徐州、成都、杭州、桂林、武汉、沈阳、济南、福州、西安、赣州、郑州、重庆、银川、长春、长沙

  5. 正在招募
    Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
    分期
    I/II期
    开始
    2022-12
    登记号
    NCT05652920

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心上海、北京、成都、杭州、长春、长沙

  6. 正在招募
    Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
    分期
    I/II期
    开始
    2021-11
    登记号
    NCT05024214

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 16 家列出的医院为研究中心上海、北京、哈尔滨、大连、天津、广州、杭州、沈阳、珠海、福州、蚌埠、郑州、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后免疫与靶向药物影像、人工智能与早期发现
论文中的科室普外/肝胆胰外科消化/肝病科放疗科病理/检验科
牵头的论文76
  1. Combined treatments based on interventional therapy improve the prognosis of patients with HCC: an umbrella review of systematic reviews and meta-analyses.2026European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  2. Molecular Dissection of the AHR-AREG driven EGFR-ERK1/2-CyclinD1 axis in acquired lenvatinib resistance of Hepatocellular carcinoma.2025Biochemical pharmacology
  3. Transarterial chemoembolization combined with tyrosine kinase inhibitors and/or immune checkpoint inhibitors induced hypothyroidism is associated with improved overall survival in hepatocellular carcinoma.2025Cancer immunology, immunotherapy : CII免费全文
  4. Sex disparities in hepatocellular carcinoma immunotherapy: hormonal and genetic influences on treatment efficacy.2025Frontiers in immunology免费全文
  5. The role of TACE in the era of immune-targeted therapy for hepatocellular carcinoma: a meta-analysis based on PSM.2025Frontiers in immunology免费全文
  6. Post-translational modifications in hepatocellular carcinoma: unlocking new frontiers in immunotherapy.2025Frontiers in immunology免费全文
  7. Comparison between models for detecting hepatocellular carcinoma in patients with chronic liver diseases of various etiologies: ASAP score versus GALAD score.2025Hepatobiliary & pancreatic diseases international : HBPD INT
  8. Integrated analysis and experimental validation reveal the prognostic and immunological features associated with coagulation in hepatocellular carcinoma.2025Scientific reports免费全文
  9. Radiotherapy with targeted and immunotherapy improved overall survival and progression-free survival for hepatocellular carcinoma with portal vein tumor thrombosis.2025The oncologist免费全文
  10. Dual-molecular targeting nanomedicine upregulates synergistic therapeutic efficacy in preclinical hepatoma models.2024Acta biomaterialia
  11. Enhancing Radiofrequency Ablation for Hepatocellular Carcinoma: Nano-Epidrug Effects on Immune Modulation and Antigenicity Restoration.2024Advanced materials (Deerfield Beach, Fla.)
  12. Trojan-Horse Strategy Targeting the Gut-Liver Axis Modulates Gut Microbiome and Reshapes Microenvironment for Orthotopic Hepatocellular Carcinoma Therapy.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  13. The Barthel Index predicts surgical textbook outcomes following hepatectomy for elderly patients with hepatocellular carcinoma: A multicenter cohort study.2024American journal of surgery
  14. ASO Author Reflections: α-Fetoprotein in Early-Stage Hepatocellular Carcinoma (BCLC Stage 0/A): Beyond Diagnosis to Prognostication.2024Annals of surgical oncology
  15. Prognostic Value of Serum α-Fetoprotein Level as an Important Characteristic of Tumor Biology for Patients Undergoing Liver Resection of Early-Stage Hepatocellular Carcinoma (BCLC Stage 0/A): A Large Multicenter Analysis.2024Annals of surgical oncology
  16. Targeting metabolic reprogramming in hepatocellular carcinoma to overcome therapeutic resistance: A comprehensive review.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  17. Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of hepatocellular carcinoma (HCC).2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  18. miR-4461 inhibits liver cancer stem cells expansion and chemoresistance via regulating SIRT1.2024Carcinogenesis
  19. AZD1775 and anti-PD-1 antibody synergistically sensitize hepatoma to radiotherapy.2024Chinese medical journal免费全文
  20. Stratifying risk of failure to achieve textbook outcomes among patients undergoing hepatectomy for hepatocellular carcinoma: A multicenter score validation study.2024European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  21. Comparison of adjuvant treatment regimens for high-risk hepatocellular carcinoma: a Bayesian network meta analysis and systematic review.2024Frontiers in immunology免费全文
  22. Unraveling the role of ADAMs in clinical heterogeneity and the immune microenvironment of hepatocellular carcinoma: insights from single-cell, spatial transcriptomics, and bulk RNA sequencing.2024Frontiers in immunology免费全文
  23. Efficacy of ginseng-based Renshenguben oral solution for cancer-related fatigue among patients with advanced-stage hepatocellular carcinoma: A prospective multicenter cohort study.2024Hepatobiliary & pancreatic diseases international : HBPD INT
  24. In-situ-formed immunotherapeutic and hemostatic dual drug-loaded nanohydrogel for preventing postoperative recurrence of hepatocellular carcinoma.2024Journal of controlled release : official journal of the Controlled Release Society
  25. Molecular mechanisms of TACE refractoriness: Directions for improvement of the TACE procedure.2024Life sciences
  26. A novel disulfidptosis-related lncRNA signature for predicting prognosis and potential targeted therapy in hepatocellular carcinoma.2024Medicine免费全文
  27. Roles of cGAS-STING Pathway in Radiotherapy Combined with Immunotherapy for Hepatocellular Carcinoma.2024Molecular cancer therapeutics
  28. Compromised macrophages contribute to progression of MASH to hepatocellular carcinoma in FGF21KO mice.2024Science advances免费全文
  29. Ultrasound-triggered nano delivery of lenvatinib for selective immunotherapy treatment against hepatocellular carcinoma.2024Scientific reports免费全文
  30. Renal Clearable Nanodots-Engineered Erythrocytes with Enhanced Circulation and Tumor Accumulation for Photothermal Therapy of Hepatocellular Carcinoma.2024Small (Weinheim an der Bergstrasse, Germany)
  31. Development and validation of nomograms to predict survival and recurrence after hepatectomy for intermediate/advanced (BCLC stage B/C) hepatocellular carcinoma.2024Surgery
  32. Proteomic and phosphoproteomic profiling of urinary small extracellular vesicles in hepatocellular carcinoma.2024The Analyst
  33. Prognostic significance of nodular number in patients undergoing hepatectomy of intermediate-stage hepatocellular carcinoma.2024The British journal of surgery
  34. Leveraging SEER data through machine learning to predict distant lymph node metastasis and prognosticate outcomes in hepatocellular carcinoma patients.2024The journal of gene medicine
  35. LncRNA NKILA inhibits HBV replication by repressing NF-κB signalling activation.2024Virologica Sinica免费全文
  36. Letter: Rethinking the lower incidence of HCC in HIV-infected patients- A closer look at confounding factors.2023Alimentary pharmacology & therapeutics
  37. Severe pleural effusion after hepatectomy for hepatocellular carcinoma: multicentre retrospective study.2023BJS open免费全文
  38. Refinement and validation of a comprehensive clinical diagnostic model (GAMAD) based on gender, age, multitarget circulating tumour DNA methylation signature and commonly used serological biomarkers for early detection of hepatocellular car2023BMJ open免费全文
  39. Tumor biology, immune infiltration and liver function define seven hepatocellular carcinoma subtypes linked to distinct drivers, survival and drug response.2023Computers in biology and medicine
  40. Progress on the molecular mechanism of portal vein tumor thrombosis formation in hepatocellular carcinoma.2023Experimental cell research
  41. Adjuvant immunotherapy improves recurrence-free and overall survival following surgical resection for intermediate/advanced hepatocellular carcinoma a multicenter propensity matching analysis.2023Frontiers in immunology免费全文
  42. Bibliometric study of immunotherapy for hepatocellular carcinoma.2023Frontiers in immunology免费全文
  43. Unveiling efferocytosis-related signatures through the integration of single-cell analysis and machine learning: a predictive framework for prognosis and immunotherapy response in hepatocellular carcinoma.2023Frontiers in immunology免费全文
  44. Single-cell RNA sequencing highlights the role of PVR/PVRL2 in the immunosuppressive tumour microenvironment in hepatocellular carcinoma.2023Frontiers in immunology免费全文
  45. From clinical variables to multiomics analysis: a margin morphology-based gross classification system for hepatocellular carcinoma stratification.2023Gut免费全文
  46. Conversion therapy in liver transplantation for hepatocellular carcinoma: What's new in the era of molecular and immune therapy?2023Hepatobiliary & pancreatic diseases international : HBPD INT
  47. Nanodelivery of scutellarin induces immunogenic cell death for treating hepatocellular carcinoma.2023International journal of pharmaceutics
  48. Delivery of melarsoprol using folate-targeted PEGylated cyclodextrin-based nanoparticles for hepatocellular carcinoma.2023International journal of pharmaceutics
  49. Liquid biopsy using cell-free DNA in the early diagnosis of hepatocellular carcinoma.2023Investigational new drugs
  50. Development and validation of a model to predict the risk of distant metastases from hepatocellular carcinoma: a real-world retrospective study.2023Journal of cancer research and clinical oncology免费全文
  51. Genetic factors in the clinical predictive model for hepatocellular carcinoma: Evidence from genetic association analyses.2023Journal of hepatology
  52. Glycoproteomic Analysis of Urinary Extracellular Vesicles for Biomarkers of Hepatocellular Carcinoma.2023Molecules (Basel, Switzerland)免费全文
  53. Pseudolaric acid B triggers cell apoptosis by activating AMPK/JNK/DRP1/mitochondrial fission pathway in hepatocellular carcinoma.2023Toxicology
  54. The miR-23-27-24 cluster: an emerging target in NAFLD pathogenesis.2022Acta pharmacologica Sinica免费全文
  55. Application of a Convolutional Neural Network for Multitask Learning to Simultaneously Predict Microvascular Invasion and Vessels that Encapsulate Tumor Clusters in Hepatocellular Carcinoma.2022Annals of surgical oncology免费全文
  56. Liver biopsy of chronic hepatitis B patients indicates HBV integration profile may complicate the endpoint and effect of entecavir treatment.2022Antiviral research
  57. Long non-coding RNA FOXP4-AS1 facilitates the biological functions of hepatocellular carcinoma cells via downregulating ZC3H12D by mediating H3K27me3 through recruitment of EZH2.2022Cell biology and toxicology免费全文
  58. Association of aspirin and nonaspirin NSAIDs therapy with the incidence risk of hepatocellular carcinoma: a systematic review and meta-analysis on cohort studies.2022European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  59. Associations between Extracellular Matrix Protein 1 Gene Polymorphism and Progression of Liver Disease.2022Genetics research免费全文
  60. Canthaxanthin shows anti-liver aging and anti-liver fibrosis effects by down-regulating inflammation and oxidative stress in vivo and in vitro.2022International immunopharmacology
  61. Polymeric nanomedicines for the treatment of hepatic diseases.2022Journal of nanobiotechnology免费全文
  62. Epidemic characteristics of alcohol-related liver disease in Asia from 2000 to 2020: A systematic review and meta-analysis.2022Liver international : official journal of the International Association for the Study of the Liver
  63. Bioinformatic identification of differentially expressed genes associated with hepatocellular carcinoma prognosis.2022Medicine免费全文
  64. Prognostic significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib: A retrospective analysis.2022Medicine免费全文
  65. Diagnostic performance of circulating tumor DNA as a minimally invasive biomarker for hepatocellular carcinoma: a systematic review and meta-analysis.2022PeerJ免费全文
  66. Type-III interferon stimulated gene TRIM31 mutation in an HBV patient blocks its ability in promoting HBx degradation.2022Virus research
  67. The mononuclear phagocyte system in hepatocellular carcinoma.2022World journal of gastroenterology免费全文
  68. Ataxia telangiectasia mutated inhibitor-loaded copper sulfide nanoparticles for low-temperature photothermal therapy of hepatocellular carcinoma.2021Acta biomaterialia
  69. PDLIM2 prevents the malignant phenotype of hepatocellular carcinoma cells by negatively regulating β-catenin.2021Cancer gene therapy
  70. Lysionotin induces apoptosis of hepatocellular carcinoma cells via caspase-3 mediated mitochondrial pathway.2021Chemico-biological interactions
  71. Establishing peripheral PD-L1 as a prognostic marker in hepatocellular carcinoma patients: how long will it come true?2021Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  72. A novel online calculator based on noninvasive markers (ALBI and APRI) for predicting post-hepatectomy liver failure in patients with hepatocellular carcinoma.2021Clinics and research in hepatology and gastroenterology
  73. Aberrant FGFR4 signaling worsens nonalcoholic steatohepatitis in FGF21KO mice.2021International journal of biological sciences免费全文
  74. Shikonin differentially regulates glucose metabolism via PKM2 and HIF1α to overcome apoptosis in a refractory HCC cell line.2021Life sciences
  75. Synthesis and Anti-Hepatocarcinoma Effect of Amino Acid Derivatives of Pyxinol and Ocotillol.2021Molecules (Basel, Switzerland)免费全文
  76. XPD Polymorphisms and Risk of Hepatocellular Carcinoma and Gastric Cancer: A Meta-Analysis.2021Technology in cancer research & treatment免费全文
中文论文(未计入)1
  1. [Advances and controversies of statins application in prevention and treatment of hepatocellular carcinoma].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
它在 ClinicalTrials.gov 上的全部试验(任何状态)28
  1. Hybrid Deep Learning Integrating Multimodal CEUS and Enhanced MRI to Optimize Early-Stage HCC Treatment Decisions即将招募NCT07582419牵头方2026-04 启动
  2. Standing Position Ultrasonography: Imaging Efficacy in Detecting Liver Diaphragmatic Dome Blind Area Lesions已完成NCT07579533牵头方2024-02 启动
  3. Contrast-Enhanced Ultrasound for Early Assessment of Microwave Ablation in HCC已完成NCT07598331牵头方不分期2021-06 启动
  4. A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC正在招募NCT07547553研究中心I/II期2026-05 启动
  5. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression正在招募NCT07327034研究中心II期2025-06 启动
  6. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma正在招募NCT07176650研究中心I期2025-11 启动
  7. Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC正在招募NCT05652920研究中心I/II期2022-12 启动
  8. Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors正在招募NCT05024214研究中心I/II期2021-11 启动
  9. A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC已撤回NCT05212922研究中心II期2023-06 启动
  10. A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)进行中,不再招募NCT05904886研究中心III期2023-09 启动
  11. SynOV1.1 Intratumoral Injection Study状态不明NCT04612504研究中心I期2022-06 启动
  12. PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma已完成NCT05864105研究中心II期2022-04 启动
  13. Refinement and Validation of a Diagnostic Model (GAMAD) for Early Detection of Hepatocellular Carcinoma状态不明NCT05626985研究中心2022-10 启动
  14. Treatment of MB07133 Plus Sintilimab in Patients With Hepatocellular Carcinoma状态不明NCT06141109研究中心I/II期2022-01 启动
  15. A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma已终止NCT05653427研究中心II期2022-12 启动
  16. A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor进行中,不再招募NCT04008797研究中心I/II期2019-07 启动
  17. A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC已完成NCT03764293研究中心III期2019-06 启动
  18. A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation已完成NCT04102098研究中心III期2019-12 启动
  19. Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) Subjects已终止NCT03591965研究中心II期2018-08 启动
  20. Prospective Surveillance for Very Early Hepatocellular Carcinoma状态不明NCT03588442研究中心2018-07 启动
  21. A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma已完成NCT03434379研究中心III期2018-03 启动
  22. Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)已完成NCT03062358研究中心III期2017-04 启动
  23. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)已完成NCT03412773研究中心III期2017-12 启动
  24. The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects已终止NCT03236649研究中心III期2017-09 启动
  25. The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects状态不明NCT03236636研究中心III期2017-09 启动
  26. A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC已完成NCT03516071研究中心II期2017-05 启动
  27. Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)已完成NCT02112656研究中心III期2014-06 启动
  28. Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)已完成NCT00617981研究中心III期2008-05 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 41 篇,占 0.4%。

牵头论文
41
2021–2025 年
牵头试验
16
任何状态,ClinicalTrials.gov
牵头的开放试验
7
正在或即将招募
作为研究中心的开放试验
7
由其他机构牵头
每年牵头的论文数
2021: 7720212022: 8820222023: 7720232024: 101020242025: 882025

长春有 4 家医院列在胃癌下全国有 211 家医院列在胃癌下

这家医院参与的开放试验 14

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Laparoscopic-endoscopic Surgery Assisted Sentinel Lymph Node Navigation Surgery for Early Gastric Cancer
    分期
    不分期
    开始
    2026-05
    登记号
    NCT07615374

    年龄未注明(登记的条件)

    牵头:吉林大学第一医院长春

  2. 正在招募
    The PRE-VAIL Study
    分期
    不分期
    开始
    2025-09
    登记号
    NCT07176624

    年龄 18 岁 至 未注明(登记的条件)

    牵头:吉林大学第一医院长春

  3. 正在招募
    Distribution Characteristics of Helicobacter Pylori
    分期
    未注明
    开始
    2025-10
    登记号
    NCT07253948

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:吉林大学第一医院长春

  4. 正在招募
    The Safety and Efficacy of Robotic Assisted Surgery Using Vessel Sealer Extend in Locally Advanced Gastric Cancer
    分期
    未注明
    开始
    2024-11
    登记号
    NCT06881043

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:吉林大学第一医院长春

  5. 正在招募
    The Effect of Different Digestive Tract Reconstruction Methods on Postoperative Quality of Life After Proximal Gastrectomy
    分期
    未注明
    开始
    2024-11
    登记号
    NCT06929949

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:吉林大学第一医院长春

  6. 正在招募
    Effect of Goal-Oriented Albumin Infusion on Postoperative Complication Management in Gastric Cancer Surgery
    分期
    II期
    开始
    2024-10
    登记号
    NCT07119463

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:吉林大学第一医院长春

  7. 即将招募
    PD-1-M1-NK Cells in the Treatment of Advanced Gastric or Colorectal Cancer
    分期
    I期
    开始
    2025-06
    登记号
    NCT07031011

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:吉林大学第一医院长春

  8. 正在招募
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    分期
    III期
    开始
    2026-04
    登记号
    NCT07385703

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 64 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南充、南昌、厦门、合肥、天津、太原、安阳、常州、广州、徐州、成都、扬州、承德、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、海口、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛

  9. 正在招募
    Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
    分期
    III期
    开始
    2026-12
    登记号
    NCT07789184

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 25 家列出的医院为研究中心上海、乌鲁木齐、北京、南京、南昌、大连、天津、广州、杭州、武汉、济南、西安、重庆、长春、青岛

  10. 正在招募
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    分期
    未注明
    开始
    2025-02
    登记号
    NCT06846996

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 32 家列出的医院为研究中心上海、北京、南京、台州、天津、太原、广州、徐州、杭州、汕头、沈阳、海口、福州、郑州、长春

  11. 正在招募
    Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
    分期
    I/II期
    开始
    2024-06
    登记号
    NCT06324357

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心上海、南京、哈尔滨、天津、杭州、郑州、长春

  12. 正在招募
    A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
    分期
    III期
    开始
    2024-11
    登记号
    NCT06532006

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 36 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、常州、广州、徐州、成都、杭州、洛阳、石家庄、福州、蚌埠、西宁、郑州、重庆、银川、长春、长沙、青岛

  13. 正在招募
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    分期
    I/II期
    开始
    2022-01
    登记号
    NCT05150691

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 34 家列出的医院为研究中心上海、北京、南宁、厦门、合肥、天津、安阳、广州、徐州、无锡、杭州、武汉、沈阳、济南、温州、烟台、石家庄、蚌埠、西安、郑州、重庆、长春、长沙

  14. 正在招募
    OGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap Method
    分期
    不分期
    开始
    2022-09
    登记号
    NCT05450835

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:南方医科大学南方医院;另有 7 家列出的医院为研究中心广州、汕头、沈阳、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题腹膜转移与晚期免疫与靶向药物早期发现与内镜
论文中的科室消化/肝病科病理/检验科放疗科临床试验/研究机构
牵头的论文41
  1. The Clinical Prognostic Value of Lactylation-Regulated Proteins in Gastric Cancer.2026Journal of proteome research免费全文
  2. RGS1 can serve as a long-term prognostic marker in gastric cancer by promoting the infiltration and polarization of macrophages.2025Biochimica et biophysica acta. Molecular basis of disease
  3. Periodontal disease and gastric and colorectal cancers: mechanisms and therapeutic perspectives.2025Frontiers in cellular and infection microbiology免费全文
  4. Recent progress in the study of exosomes in the gastric cancer immune microenvironment.2025Frontiers in immunology免费全文
  5. Protein phosphatase 1 regulatory subunit 15 A (PPP1R15A) promoted the progression of gastric cancer by activating cell autophagy under energy stress.2025Journal of experimental & clinical cancer research : CR免费全文
  6. Gastric cancer-related mortality in the United States from 1999 to 2023.2025Medicine免费全文
  7. Roles of plasma proteins in mediating the causal effect of the lipid species on gastric cancer: Insights from proteomic and two-step Mendelian randomization.2025Medicine免费全文
  8. 5-hydroxymethylcytosines from circulating cell-free DNA as noninvasive prognostic markers for gastric cancer.2025PloS one免费全文
  9. Integrative pan-cancer analysis and experiment validation identified GLS as a biomarker in tumor progression, prognosis, immune microenvironment, and immunotherapy.2025Scientific reports免费全文
  10. Postoperative therapy for local-advanced gastric cancer: A systematic review and meta-analysis.2024Advances in clinical and experimental medicine : official organ Wroclaw Medical University
  11. Exploration of signature based on T cell-related genes in stomach adenocarcinoma by analysis of single cell sequencing data.2024Aging免费全文
  12. Utilizing serum metabolomics for assessing postoperative efficacy and monitoring recurrence in gastric cancer patients.2024BMC cancer免费全文
  13. Deficiency in SPOP-mediated ubiquitination and degradation of TIAM1 promotes gastric cancer progression.2024Biochimica et biophysica acta. Molecular basis of disease
  14. Lung enteric-type adenocarcinoma with gastric metastasis: a rare case report and literature review.2024Frontiers in immunology免费全文
  15. Genome-wide 5-hydroxymethylcytosines in circulating cell-free DNA as noninvasive diagnostic markers for gastric cancer.2024Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  16. Appraising associations between signature lipidomic biomarkers and digestive system cancer risk: novel evidences from a prospective cohort study of UK Biobank and Mendelian randomization analyses.2024Lipids in health and disease免费全文
  17. A case of malignant gastric glomus tumor and literature review: A case report.2024Medicine免费全文
  18. Development and validation of self-screening tool for nutrition risk in patients with gastric cancer after gastrectomy: A study protocol.2024Nursing open免费全文
  19. Nine-Gene Prognostic Signature Related to Gut Microflora for Predicting the Survival in Gastric Cancer Patients.2024The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology免费全文
  20. Emphasis on the clinical relationship between alpha-fetoprotein and hepatoid adenocarcinoma of the stomach: a retrospective study.2023BMC gastroenterology免费全文
  21. TRIP 13-dependent pathways promote the development of gastric cancer.2023Functional & integrative genomics免费全文
  22. KLF3 Transcription Activates WNT1 and Promotes the Growth and Metastasis of Gastric Cancer via Activation of the WNT/β-Catenin Signaling Pathway.2023Laboratory investigation; a journal of technical methods and pathology
  23. Predictive value of hepatitis B serological indicators for mortality among cancer survivors and validation in a gastric cancer cohort.2023PloS one免费全文
  24. Gastric defect closure after endoscopic full-thickness resection: the closing while dissecting technique.2023Surgical endoscopy
  25. MoS2 QDs-MXene heterostructure-based ECL sensor for the detection of miRNA-135b in gastric cancer exosomes.2023Talanta
  26. Advances and key focus areas in gastric cancer immunotherapy: A comprehensive scientometric and clinical trial review (1999-2023).2023World journal of gastroenterology免费全文
  27. Positive H. pylori status predicts better prognosis of non-cardiac gastric cancer patients: results from cohort study and meta-analysis.2022BMC cancer免费全文
  28. A glutathione-responsive sulfur dioxide polymer prodrug selectively induces ferroptosis in gastric cancer therapy.2022Biomaterials science
  29. circXRCC5 foster gastric cancer growth and metastasis by the HNRNPC/circXRCC5/miR-655-3p/RREB1/UBA2 positive feedback loop.2022Cancer gene therapy
  30. Exosome-mediated lncRNA SND1-IT1 from gastric cancer cells enhances malignant transformation of gastric mucosa cells via up-regulating SNAIL1.2022Journal of translational medicine免费全文
  31. DEK modulates both expression and alternative splicing of cancer‑related genes.2022Oncology reports免费全文
  32. Development and verification of an immune-related gene prognostic index for gastric cancer.2022Scientific reports免费全文
  33. Functional genomics screening identifies aspartyl-tRNA synthetase as a novel prognostic marker and a therapeutic target for gastric cancers.2022The Journal of pathology
  34. Development of cancer-associated fibroblasts subtype and prognostic model in gastric cancer and the landscape of tumor microenvironment.2022The international journal of biochemistry & cell biology
  35. Gene expression barcode values reveal a potential link between Parkinson's disease and gastric cancer.2021Aging免费全文
  36. Up-regulation of DGAT1 in cancer tissues and tumor-infiltrating macrophages influenced survival of patients with gastric cancer.2021BMC cancer免费全文
  37. The emerging role of miR-10 family in gastric cancer.2021Cell cycle (Georgetown, Tex.)免费全文
  38. MiR-10b-5p inhibits tumorigenesis in gastric cancer xenograft mice model through down-regulating Tiam1.2021Experimental cell research
  39. Targeting miR-148b-5p Inhibits Immunity Microenvironment and Gastric Cancer Progression.2021Frontiers in immunology免费全文
  40. Mucosal microbial microenvironment in early gastric neoplasia and non-neoplastic gastric disease.2021Journal of gastroenterology and hepatology
  41. XPD Polymorphisms and Risk of Hepatocellular Carcinoma and Gastric Cancer: A Meta-Analysis.2021Technology in cancer research & treatment免费全文
中文论文(未计入)1
  1. [Pylorus-preserving gastrectomy and segmental gastrectomy: discrimination of concepts and surgical procedures].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)45
  1. The PRE-VAIL Study正在招募NCT07176624牵头方不分期2025-09 启动
  2. The Safety and Efficacy of Robotic Assisted Surgery Using Vessel Sealer Extend in Locally Advanced Gastric Cancer正在招募NCT06881043牵头方2024-11 启动
  3. Effect of Goal-Oriented Albumin Infusion on Postoperative Complication Management in Gastric Cancer Surgery正在招募NCT07119463牵头方II期2024-10 启动
  4. The Effect of Different Digestive Tract Reconstruction Methods on Postoperative Quality of Life After Proximal Gastrectomy正在招募NCT06929949牵头方2024-11 启动
  5. A Prospective, Single Center Clinical Study of Toripalimab Combined With FLOT Regimen for Perioperative Treatment of PD-L1 Positive Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GEJ)状态不明NCT05466019牵头方II期2021-05 启动
  6. The Safety and Efficacy of PD-1 Monoantrapical Chemotherapy in the Treatment of Local Advanced Stomach Cancer状态不明NCT05000554牵头方II期2021-07 启动
  7. Radical Gastrectomy Within Enhanced Recovery Programs(ERAS): a Prospective Randomized Controlled Trial状态不明NCT03046303牵头方不分期2017-02 启动
  8. Efficacy of Preoperative Nutritional Support on Postoperative Outcome in Gastric Cancer Patients at Nutritional Risk by NRS-2002已完成NCT01830907牵头方早期I期2012-01 启动
  9. Laparoscopic-endoscopic Surgery Assisted Sentinel Lymph Node Navigation Surgery for Early Gastric Cancer正在招募NCT07615374牵头方(推断)不分期2026-05 启动
  10. PD-1-M1-NK Cells in the Treatment of Advanced Gastric or Colorectal Cancer即将招募NCT07031011牵头方(推断)I期2025-06 启动
  11. Distribution Characteristics of Helicobacter Pylori正在招募NCT07253948牵头方(推断)2025-10 启动
  12. Microbiota and Metabolomics of Intestinal Type of Gastric Cancer状态不明NCT06079554牵头方(推断)2024-03 启动
  13. The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer已完成NCT04694183牵头方(推断)II期2020-08 启动
  14. Spleen-Preserving No. 10 Lymph Node Dissection in Gastric Cancer状态不明NCT04050787牵头方(推断)不分期2019-07 启动
  15. Uncut Roux-en-Y vs Roux-en-Y状态不明NCT03349398牵头方(推断)不分期2017-11 启动
  16. The Advantages and Disadvantages Between Uncut Roux-en-Y Reconstruction and Billroth II Reconstruction After Laparoscopy-assisted Distal Gastrectomy for Gastric状态不明NCT02694081牵头方(推断)II期2016-02 启动
  17. Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy正在招募NCT07789184研究中心III期2026-12 启动
  18. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.正在招募NCT07385703研究中心III期2026-04 启动
  19. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China正在招募NCT06846996研究中心2025-02 启动
  20. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer正在招募NCT06532006研究中心III期2024-11 启动
  21. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread正在招募NCT06324357研究中心I/II期2024-06 启动
  22. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors正在招募NCT05150691研究中心I/II期2022-01 启动
  23. OGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap Method正在招募NCT05450835研究中心不分期2022-09 启动
  24. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression已完成NCT05052801研究中心III期2022-03 启动
  25. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.已终止NCT05111626研究中心III期2022-03 启动
  26. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer进行中,不再招募NCT05180734研究中心III期2022-02 启动
  27. Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)进行中,不再招募NCT04704934研究中心III期2021-05 启动
  28. Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension已完成NCT04882241研究中心III期2020-07 启动
  29. Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis状态不明NCT04222114研究中心III期2020-10 启动
  30. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)进行中,不再招募NCT04152499研究中心I/II期2020-02 启动
  31. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection进行中,不再招募NCT04581473研究中心I/II期2020-10 启动
  32. A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer Diagnosis状态不明NCT04440605研究中心2020-07 启动
  33. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer状态不明NCT04486651研究中心III期2020-09 启动
  34. A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer已完成NCT04053205研究中心I/II期2019-11 启动
  35. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)已完成NCT03675737研究中心III期2018-11 启动
  36. Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers状态不明NCT03468712研究中心不分期2018-03 启动
  37. A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer已完成NCT03694522研究中心II期2018-09 启动
  38. Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)已完成NCT03615326研究中心III期2018-10 启动
  39. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension已撤回NCT04859582研究中心III期2018-11 启动
  40. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC状态不明NCT02915432研究中心I/II期2016-12 启动
  41. Study of Metatinib Tromethamine Tablet状态不明NCT02650375研究中心I期2015-10 启动
  42. A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer已完成NCT02178956研究中心III期2014-10 启动
  43. A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer已完成NCT01774786研究中心III期2013-06 启动
  44. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer已完成NCT01839500研究中心2013-04 启动
  45. A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer已终止NCT01641939研究中心II/III期2012-09 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

肝母细胞瘤

Hepatoblastoma

2021–2025 年中国大陆作者发表的 154 篇肝母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

长春有 1 家医院列在肝母细胞瘤下全国有 86 家医院列在肝母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。

这些数字背后的记录
论文中的科室儿科
牵头的论文1
  1. Incidence trends and a nomogram for predicting overall survival in children with hepatoblastoma: A population-based analysis.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
早期论文(2016–2020 年)3
  1. Novel treatment of refractory / recurrent pulmonary hepatoblastoma.2020Pediatrics international : official journal of the Japan Pediatric Society
  2. Wnt/β-catenin signaling as a useful therapeutic target in hepatoblastoma.2019Bioscience reports
  3. Kockdown of OIP5-AS1 expression inhibits proliferation, metastasis and EMT progress in hepatoblastoma cells through up-regulating miR-186a-5p and down-regulating ZEB1.2018Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.0%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

长春有 3 家医院列在视网膜母细胞瘤下全国有 176 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录
论文中的科室眼科/神经眼科

打开 PubMed 检索ClinicalTrials.gov

癌症

脊索瘤

Chordoma

2021–2025 年没有牵头脊索瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

长春有 2 家医院列在脊索瘤下全国有 84 家医院列在脊索瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Primary maxillofacial chordoma: a rare case report and literature review.2019The Journal of international medical research

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 17 篇,占 0.8%。

牵头论文
17
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 5520212022: 8820222023: 1120232024: 2220242025: 002025

长春有 4 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室影像/核医学科

这些论文过半是实验室或动物研究。

牵头的论文17
  1. Multifunctional poly(amino acid) nanomedicine modulates macrophage polarization for osteosarcoma immunotherapy.2026Journal of controlled release : official journal of the Controlled Release Society
  2. Biomaterials-Boosted Immunotherapy for Osteosarcoma.2024Advanced healthcare materials
  3. The role of neutrophils in osteosarcoma: insights from laboratory to clinic.2024Frontiers in immunology
  4. Single-cell RNA datasets and bulk RNA datasets analysis demonstrated C1Q+ tumor-associated macrophage as a major and antitumor immune cell population in osteosarcoma.2023Frontiers in immunology
  5. Effective natural inhibitors targeting IGF-1R by computational study.2022Aging
  6. MiR-659-3p inhibits osteosarcoma progression and metastasis by inhibiting cell proliferation and invasion via targeting SRPK1.2022BMC cancer
  7. SRPK1 promotes cell proliferation and tumor growth of osteosarcoma through activation of the NF-κB signaling pathway.2022Biological chemistry
  8. Colorimetric identification of miRNA-195 sequence for diagnosing osteosarcoma.2022Biotechnology and applied biochemistry
  9. Identification of PSMD14 as a potential novel prognosis biomarker and therapeutic target for osteosarcoma.2022Cancer reports (Hoboken, N.J.)
  10. Deduction of CDC42EP3 suppress development and progression of osteosarcoma.2022Experimental cell research
  11. Modulation of immunosuppressive cells and noncoding RNAs as immunotherapy in osteosarcoma.2022Frontiers in immunology
  12. Role of extracellular vesicles in osteosarcoma.2022International journal of medical sciences
  13. Selected using bioinformatics and molecular docking analyses, PHA-793887 is effective against osteosarcoma.2021Aging
  14. Circular RNA circPVT1 Contributes to Doxorubicin (DXR) Resistance of Osteosarcoma Cells by Regulating TRIAP1 via miR-137.2021BioMed research international
  15. Breast osteosarcoma originating from a malignant phyllodes tumor: A case report of a rare neoplasm.2021Medicine
  16. Ginsenoside Rg5 Inhibits Human Osteosarcoma Cell Proliferation and Induces Cell Apoptosis through PI3K/Akt/mTORC1-Related LC3 Autophagy Pathway.2021Oxidative medicine and cellular longevity
  17. The roles of metastasis-related proteins in the development of giant cell tumor of bone, osteosarcoma and Ewing's sarcoma.2021Technology and health care : official journal of the European Society for Engineering and Medicine
中文论文(未计入)1
  1. [Bioinformatics-based identification of key genes CDC5L and related pathways in osteosarcoma and Ewing's sarcoma].2022Zhongguo gu shang = China journal of orthopaedics and traumatology
早期论文(2016–2020 年)18
  1. LncRNA DLEU2 promotes tumour growth by sponging miR-337-3p in human osteosarcoma.2020Cell biochemistry and function
  2. Application of tumor-targeting peptide-decorated polypeptide nanoparticles with doxorubicin to treat osteosarcoma.2020Drug delivery
  3. Long noncoding RNA PVT1 promotes metastasis via miR-484 sponging in osteosarcoma cells.2020European review for medical and pharmacological sciences
  4. Circular RNA PVT1 promotes metastasis via regulating of miR-526b/FOXC2 signals in OS cells.2020Journal of cellular and molecular medicine
  5. A multiple drug loaded, functionalized pH-sensitive nanocarrier as therapeutic and epigenetic modulator for osteosarcoma.2020Scientific reports
  6. Primary Pediatric Renal Primitive Neuroectodermal Tumor: A Case Report With Different Stage CT and MRI Images.2020Urology
  7. LncRNA HIF2PUT inhibited osteosarcoma stem cells proliferation, migration and invasion by regulating HIF2 expression.2019Artificial cells, nanomedicine, and biotechnology
  8. Interleukin-35 suppresses antitumor activity of circulating CD8+ T cells in osteosarcoma patients.2019Connective tissue research
  9. In Vitro Generation of Anti-Osteosarcoma Cytotoxic Activity Using Dendritic Cells Loaded with Heat Shock Protein 70-Peptide Complexes.2019Fetal and pediatric pathology
  10. The effect of PLGA-based hydrogel scaffold for improving the drug maximum-tolerated dose for in situ osteosarcoma treatment.2018Colloids and surfaces. B, Biointerfaces
  11. miR‑15a represses cancer cell migration and invasion under conditions of hypoxia by targeting and downregulating Bcl‑2 expression in human osteosarcoma cells.2018International journal of oncology
  12. lncRNA LINC01296 regulates the proliferation, metastasis and cell cycle of osteosarcoma through cyclin D1.2018Oncology reports
  13. MicroRNA-152 Suppresses Human Osteosarcoma Cell Proliferation and Invasion by Targeting E2F Transcription Factor 3.2018Oncology research
  14. Rare adrenal gland incidentaloma: an unusual Ewing's sarcoma family of tumor presentation and literature review.2017BMC urology
  15. Prognostic implications of RB1 tumour suppressor gene alterations in the clinical outcome of human osteosarcoma: a meta-analysis.2017European journal of cancer care
  16. [Ewing's sarcoma misdiagnosed as nonossifying fibroma: a case report].2017Zhongguo gu shang = China journal of orthopaedics and traumatology
  17. A polysaccharide from the leaves of Aralia elata induces apoptosis in U-2 OS cells via mitochondrial-dependent pathway.2016International journal of biological macromolecules
  18. Shock wave-induced ATP release from osteosarcoma U2OS cells promotes cellular uptake and cytotoxicity of methotrexate.2016Journal of experimental & clinical cancer research : CR

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年没有牵头胃肠道间质瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

长春有 5 家医院列在胃肠道间质瘤下全国有 240 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 7 篇,占 0.6%。

牵头论文
7
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 2220222023: 3320232024: 0020242025: 002025

长春有 3 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室儿科神经外科神经内科普外/肝胆胰外科

这些论文过半是实验室或动物研究。

牵头的论文7
  1. Deficiency of BAP1 inhibits neuroblastoma tumorigenesis through destabilization of MYCN.2023Cell death & disease
  2. Oxidative stress as a key event in 2,6-dichloro-1,4-benzoquinone-induced neurodevelopmental toxicity.2023Ecotoxicology and environmental safety
  3. Maltol inhibits oxygen glucose deprivation‑induced chromatinolysis in SH‑SY5Y cells by maintaining pyruvate level.2023Molecular medicine reports
  4. Different tumorigenicity and distinct metastasis and gene signature between orthotopic and subcutaneous neuroblastoma xenografted mice.2022Aging
  5. DYT6 mutated THAP1 is a cell type dependent regulator of the SP1 family.2022Brain : a journal of neurology
  6. Low-viscosity sodium alginate combined with TiO2 nanoparticles for improving neuroblastoma treatment.2021International journal of biological macromolecules
  7. Undifferentiated embryonal sarcoma of the liver with epithelioid features in an adult patient: A case report.2021Medicine
早期论文(2016–2020 年)12
  1. A five-gene signature derived from m6A regulators to improve prognosis prediction of neuroblastoma.2020Cancer biomarkers : section A of Disease markers
  2. Role and toxicity of radiation therapy in neuroblastoma patients: A literature review.2020Critical reviews in oncology/hematology
  3. An elongated tract of polyQ in the carboxyl‑terminus of human α1A calcium channel induces cell apoptosis by nuclear translocation.2020Oncology reports
  4. Silencing CASC11 curbs neonatal neuroblastoma progression through modulating microRNA-676-3p/nucleolar protein 4 like (NOL4L) axis.2020Pediatric research
  5. RNA N6-methyladenosine modification is required for miR-98/MYCN axis-mediated inhibition of neuroblastoma progression.2020Scientific reports
  6. CRMP2-derived peptide ST2-104 (R9-CBD3) protects SH-SY5Y neuroblastoma cells against Aβ25-35-induced neurotoxicity by inhibiting the pCRMP2/NMDAR2B signaling pathway.2019Chemico-biological interactions
  7. Treatment of Neuroblastoma with a Novel Delayed Intensification Chemotherapy.2019Indian journal of pediatrics
  8. Endoplasmic reticulum stress regulates oxygen-glucose deprivation-induced parthanatos in human SH-SY5Y cells via improvement of intracellular ROS.2018CNS neuroscience & therapeutics
  9. Trehalose inhibits H2O2-induced autophagic death in dopaminergic SH-SY5Y cells via mitigation of ROS-dependent endoplasmic reticulum stress and AMPK activation.2018International journal of medical sciences
  10. miR-205 Inhibits Neuroblastoma Growth by Targeting cAMP-Responsive Element-Binding Protein 1.2018Oncology research
  11. Lycopene protects human SH‑SY5Y neuroblastoma cells against hydrogen peroxide‑induced death via inhibition of oxidative stress and mitochondria‑associated apoptotic pathways.2016Molecular medicine reports
  12. Stimulus-dependent neuronal cell responses in SH-SY5Y neuroblastoma cells.2016Molecular medicine reports

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 1.2%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

长春有 3 家医院列在尤文肉瘤下全国有 134 家医院列在尤文肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 17 篇,占 1.0%。

牵头论文
17
2021–2025 年
牵头试验
6
任何状态,ClinicalTrials.gov
牵头的开放试验
4
正在或即将招募
作为研究中心的开放试验
7
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 3320222023: 6620232024: 3320242025: 222025

长春有 3 家医院列在多发性骨髓瘤下全国有 175 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 11

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia
    分期
    II期
    开始
    2025-12
    登记号
    NCT07509086

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:吉林大学第一医院长春

  2. 正在招募
    Dara-PD in the Treatment of Patients With First Relapse of Multiple Myeloma
    分期
    未注明
    开始
    2023-06
    登记号
    NCT06252792

    年龄 18 岁 至 未注明(登记的条件)

    牵头:吉林大学第一医院长春

  3. 正在招募
    Individualized Dynamic Frailty-tailored Therapy (DynaFiT) in Elderly Patients With NDMM
    分期
    未注明
    开始
    2021-09
    登记号
    NCT06099912

    年龄 65 岁 至 未注明(登记的条件)

    牵头:吉林大学第一医院长春

  4. 即将招募
    Risk-adapted Therapeutic Strategy in +1q NDMM
    分期
    未注明
    开始
    2025-09
    登记号
    NCT07045168

    年龄未注明(登记的条件)

    牵头:吉林大学第一医院长春

  5. 正在招募
    A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
    分期
    III期
    开始
    2026-05
    登记号
    NCT07518186

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心北京、南京、南昌、天津、成都、杭州、武汉、深圳、温州、西安、长春

  6. 正在招募
    68Ga-BCMA PET/CT in Multiple Myeloma
    分期
    II/III期
    开始
    2025-12
    登记号
    NCT07319897

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:北京大学第一医院;另有 2 家列出的医院为研究中心北京、石家庄、长春

  7. 正在招募
    A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
    分期
    I/II期
    开始
    2023-10
    登记号
    NCT06049290

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 20 家列出的医院为研究中心上海、北京、厦门、太原、宁波、广州、杭州、武汉、沈阳、海口、深圳、温州、芜湖、苏州、西安、贵阳、郑州、长春、青岛

  8. 正在招募
    Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
    分期
    III期
    开始
    2022-09
    登记号
    NCT05243797

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、天津、杭州、武汉、沈阳、济南、温州、郑州、长春

  9. 正在招募
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    分期
    III期
    开始
    2022-10
    登记号
    NCT05552222

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、北京、南京、南宁、南昌、厦门、哈尔滨、天津、常州、广州、成都、杭州、武汉、沈阳、济南、深圳、温州、福州、西安、郑州、重庆、长春、长沙

  10. 正在招募
    A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
    分期
    III期
    开始
    2022-11
    登记号
    NCT05623020

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、南京、天津、广州、杭州、武汉、温州、福州、苏州、长春

  11. 正在招募
    A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
    分期
    III期
    开始
    2021-10
    登记号
    NCT05020236

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 20 家列出的医院为研究中心北京、南京、南昌、天津、广州、徐州、杭州、武汉、济南、深圳、温州、石家庄、福州、郑州、重庆、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题诊断、微小残留病与危险分层复发与耐药联合用药
论文中的科室影像/核医学科肿瘤内科神经外科
牵头的论文17
  1. Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma.2025Blood reviews
  2. Development and validation of a prognostic staging system for primary plasma cell leukemia.2025Journal of hematology & oncology免费全文
  3. Dynamics of minimal residual disease and its clinical implications in multiple myeloma: A retrospective real-life analysis.2024Clinical medicine (London, England)免费全文
  4. Palmitic acid inhibits macrophage-mediated chemotherapy resistance in multiple myeloma via ALOX12 signaling.2024International immunopharmacology
  5. Individualized dynamic frailty-tailored therapy (DynaFiT) in elderly patients with newly diagnosed multiple myeloma: a prospective study.2024Journal of hematology & oncology免费全文
  6. Dynamic monitoring of minimal residual disease in newly-diagnosed multiple myeloma.2023American journal of hematology
  7. Proposed risk-scoring model for estimating the prognostic impact of 1q gain in patients with newly diagnosed multiple myeloma.2023American journal of hematology
  8. More than 2% circulating plasma cells as a prognostic biomarker in a large cohort of patients with newly-diagnosed multiple myeloma.2023Annals of hematology
  9. Early leukoencephalopathy during daratumumab treatment in a patient with multiple myeloma.2023Annals of hematology免费全文
  10. Diagnostic value of WB-DWI versus 18F-FDG PET/CT for the detection of multiple myeloma.2023Indian journal of cancer
  11. Interleukin-10 increases macrophage-mediated chemotherapy resistance via FABP5 signaling in multiple myeloma.2023International immunopharmacology
  12. The prognostic value of the MASS in a multi-center cohort of patients with newly diagnosed multiple myeloma.2022Blood cancer journal免费全文
  13. Decoding DNA methylation in epigenetics of multiple myeloma.2022Blood reviews
  14. Tetrahydrobiopterin induces proteasome inhibitor resistance and tumor progression in multiple myeloma.2022Medical oncology (Northwood, London, England)免费全文
  15. Updates to the drug-resistant mechanism of proteasome inhibitors in multiple myeloma.2021Asia-Pacific journal of clinical oncology
  16. Correlations between apparent diffusion coefficient values of WB-DWI and clinical parameters in multiple myeloma.2021BMC medical imaging免费全文
  17. Role of whole-body diffusion-weighted imaging in evaluation of multiple myeloma.2021Medicine免费全文
中文论文(未计入)1
  1. [A predictive model based on risk factors for early mortality in patients with newly diagnosed multiple myeloma].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)27
  1. IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia正在招募NCT07509086牵头方II期2025-12 启动
  2. Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone in the Treatment of the First Relapsed Multiple Myeloma状态不明NCT04063189牵头方II期2017-03 启动
  3. Risk-adapted Therapeutic Strategy in +1q NDMM即将招募NCT07045168牵头方(推断)2025-09 启动
  4. Dara-PD in the Treatment of Patients With First Relapse of Multiple Myeloma正在招募NCT06252792牵头方(推断)2023-06 启动
  5. Individualized Dynamic Frailty-tailored Therapy (DynaFiT) in Elderly Patients With NDMM正在招募NCT06099912牵头方(推断)2021-09 启动
  6. A Perspective Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment状态不明NCT06109233牵头方(推断)2022-01 启动
  7. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma正在招募NCT07518186研究中心III期2026-05 启动
  8. 68Ga-BCMA PET/CT in Multiple Myeloma正在招募NCT07319897研究中心II/III期2025-12 启动
  9. A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma正在招募NCT06049290研究中心I/II期2023-10 启动
  10. A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant正在招募NCT05623020研究中心III期2022-11 启动
  11. Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation正在招募NCT05243797研究中心III期2022-09 启动
  12. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma正在招募NCT05552222研究中心III期2022-10 启动
  13. A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments正在招募NCT05020236研究中心III期2021-10 启动
  14. A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)进行中,不再招募NCT06464991研究中心III期2024-03 启动
  15. A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT05572515研究中心III期2023-03 启动
  16. A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment进行中,不再招募NCT05455320研究中心III期2022-10 启动
  17. A Study of Daratumumab进行中,不再招募NCT05438043研究中心III期2022-12 启动
  18. A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.已完成NCT05228470研究中心II期2021-12 启动
  19. A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT05083169研究中心III期2021-10 启动
  20. A Study of Ninlaro in Real World Clinical Practice in China已完成NCT04328662研究中心2020-05 启动
  21. TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma已完成NCT03860038研究中心II期2019-01 启动
  22. A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma已完成NCT03944057研究中心II期2019-09 启动
  23. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma已完成NCT03952091研究中心III期2019-03 启动
  24. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)已完成NCT03217812研究中心III期2017-11 启动
  25. Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma已完成NCT03029234研究中心III期2017-03 启动
  26. A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma已完成NCT03234972研究中心III期2017-11 启动
  27. Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma已完成NCT01818752研究中心III期2013-07 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

B 细胞急性淋巴细胞白血病

B-cell acute lymphoblastic leukaemia

2021–2025 年没有牵头B 细胞急性淋巴细胞白血病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头

长春有 1 家医院列在B 细胞急性淋巴细胞白血病下全国有 88 家医院列在B 细胞急性淋巴细胞白血病下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Study of YK012 in B-cell Acute Lymphoblastic Leukemia
    分期
    I/II期
    开始
    2024-09
    登记号
    NCT06580301

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 8 家列出的医院为研究中心南昌、广州、徐州、杭州、贵阳、长春

  2. 即将招募
    SNC116 Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
    分期
    早期I期
    开始
    2026-09
    登记号
    NCT07830238

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. SNC116 Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia即将招募NCT07830238研究中心早期I期2026-09 启动
  2. Study of YK012 in B-cell Acute Lymphoblastic Leukemia正在招募NCT06580301研究中心I/II期2024-09 启动
  3. Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)已完成NCT03476239研究中心III期2017-10 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

再生障碍性贫血

Aplastic anaemia

2021–2025 年中国大陆作者发表的 412 篇再生障碍性贫血 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.5%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

长春有 1 家医院列在再生障碍性贫血下全国有 63 家医院列在再生障碍性贫血下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的再生障碍性贫血开放试验。

这些数字背后的记录
研究主题免疫抑制治疗促血小板生成药物
论文中的科室肾内科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

噬血细胞性淋巴组织细胞增生症

Haemophagocytic lymphohistiocytosis

2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 4 篇,占 1.0%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 332025

长春有 1 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的噬血细胞性淋巴组织细胞增生症开放试验。

这些数字背后的记录
研究主题EB病毒与感染诱因儿童诊断与预后
论文中的科室儿科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血友病 A

Haemophilia A

2021–2025 年没有牵头血友病 A的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

长春有 1 家医院列在血友病 A下全国有 132 家医院列在血友病 A下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血友病 A开放试验。

这些数字背后的记录
中文论文(未计入)1
  1. [Treatment of hemophilic arthropathy of ankle by arthrodesis with a small anterior approach:a case report].2023Zhongguo gu shang = China journal of orthopaedics and traumatology
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with Inhibitor已完成NCT06289166研究中心II期2024-03 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

非典型溶血性尿毒症综合征

Atypical haemolytic uraemic syndrome

2021–2025 年中国大陆作者发表的 27 篇非典型溶血性尿毒症综合征 PubMed 英文论文中,这家医院牵头了 2 篇,占 7.4%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

长春有 1 家医院列在非典型溶血性尿毒症综合征下全国有 31 家医院列在非典型溶血性尿毒症综合征下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的非典型溶血性尿毒症综合征开放试验。

这些数字背后的记录
论文中的科室肾内科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血栓性血小板减少性紫癜

Thrombotic thrombocytopenic purpura

2021–2025 年中国大陆作者发表的 64 篇血栓性血小板减少性紫癜 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

长春有 1 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血栓性血小板减少性紫癜开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

视神经脊髓炎谱系疾病

Neuromyelitis optica spectrum disorder

2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 11 篇,占 2.3%。

牵头论文
11
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 3320222023: 4420232024: 1120242025: 112025

长春有 2 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 即将招募
    Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial
    分期
    IV期
    开始
    2026-06
    登记号
    NCT07699770

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:空军军医大学唐都医院;另有 5 家列出的医院为研究中心北京、昆明、沈阳、西安、重庆、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题抗体与诊断急性发作治疗影像
论文中的科室神经内科
牵头的论文11
  1. Differences in clinical phenotype, laboratory, and imaging manifestations between AQP4 IgG positive and AQP4 MOG IgG double negative NMOSD: How to correctly diagnose the two.2025Autoimmunity reviews
  2. Effects of intravenous pulse methylprednisolone in neuromyelitis optica during the acute phase.2024Annals of clinical and translational neurology免费全文
  3. Discrepancy in clinical and laboratory profiles of NMOSD patients between AQP4 antibody positive and negative: can NMOSD be diagnosed without AQP4 antibody?2023Clinical and experimental immunology
  4. Causal relationships between susceptibility and severity of COVID-19 and neuromyelitis optica spectrum disorder (NMOSD) in European population: a bidirectional Mendelian randomized study.2023Frontiers in immunology免费全文
  5. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder.2023Multiple sclerosis and related disorders
  6. Oily fish and raw vegetable consumption can decrease the risk of AQP4-positive neuromyelitis optica spectrum disorders: a Mendelian-randomization study.2023Scientific reports免费全文
  7. Comparisons of clinical phenotype, radiological and laboratory features, and therapy of neuromyelitis optica spectrum disorder by regions: update and challenges.2022Autoimmunity reviews
  8. Progress in treatment of neuromyelitis optica spectrum disorders (NMOSD): Novel insights into therapeutic possibilities in NMOSD.2022CNS neuroscience & therapeutics免费全文
  9. Thrombotic thrombocytopenic purpura with neurological impairment: A Review.2022Medicine免费全文
  10. AQP4-IgG positive paraneoplastic NMOSD: A case report and review.2021Brain and behavior免费全文
  11. Clinical characteristics of MOG antibody disease: two case reports.2021Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial即将招募NCT07699770研究中心IV期2026-06 启动
PubMed 以外找到的论文(未计入)2
  1. A single-electrode system for ZIF-67 enhanced luminol electrochemiluminescence detection of AQP4 antibody2025Sensors and Actuators B Chemical论文
  2. Metal-organic frameworks-based coreactants for enhanced electrochemiluminescence detection of AQP4 antibodies2025Electrochimica Acta论文

打开 PubMed 检索ClinicalTrials.gov

其他疾病

重症肌无力

Myasthenia gravis

2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
5
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

长春有 3 家医院列在重症肌无力下全国有 89 家医院列在重症肌无力下

这家医院参与的开放试验 5

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
    分期
    I期
    开始
    2025-09
    登记号
    NCT07215650

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、天津、太原、广州、成都、福州、贵阳、郑州、长春

  2. 正在招募
    Myasthenia Gravis Registry in China
    分期
    未注明
    开始
    2024-02
    登记号
    NCT06241521

    年龄未注明(登记的条件)

    牵头:复旦大学附属华山医院;另有 15 家列出的医院为研究中心上海、北京、南昌、天津、广州、徐州、成都、苏州、西安、郑州、重庆、长春、长沙

  3. 正在招募
    A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
    分期
    II/III期
    开始
    2024-07
    登记号
    NCT06447597

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、南昌、广州、成都、杭州、武汉、济南、西安、遵义、长春、长沙

  4. 正在招募
    Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
    分期
    III期
    开始
    2024-06
    登记号
    NCT06463587

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心上海、北京、广州、成都、武汉、沈阳、石家庄、蚌埠、遵义、郑州、长春、长沙

  5. 正在招募
    A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
    分期
    III期
    开始
    2021-07
    登记号
    NCT04951622

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心上海、北京、天津、广州、成都、杭州、济南、福州、西安、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
牵头的论文1
  1. Erythroderma combined with deeper dermal dermatophytosis due to Trichophyton rubrum in a patient with myasthenia gravis: first case report and literature review.2023BMC infectious diseases免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)10
  1. Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)正在招募NCT07215650研究中心I期2025-09 启动
  2. A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.正在招募NCT06447597研究中心II/III期2024-07 启动
  3. Myasthenia Gravis Registry in China正在招募NCT06241521研究中心2024-02 启动
  4. Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)正在招募NCT06463587研究中心III期2024-06 启动
  5. A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis正在招募NCT04951622研究中心III期2021-07 启动
  6. A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis进行中,不再招募NCT06298552研究中心III期2024-04 启动
  7. Study of Telitacicept in Generalized Myasthenia Gravis已完成NCT05737160研究中心III期2023-03 启动
  8. A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis已终止NCT04963270研究中心III期2021-10 启动
  9. A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis进行中,不再招募NCT05070858研究中心III期2021-12 启动
  10. A Study of TACI(Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor)-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis已完成NCT04302103研究中心II期2020-07 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

烟雾病

Moyamoya disease

2021–2025 年中国大陆作者发表的 356 篇烟雾病 PubMed 英文论文中,这家医院牵头了 4 篇,占 1.1%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 1120232024: 0020242025: 002025

长春有 2 家医院列在烟雾病下全国有 47 家医院列在烟雾病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的烟雾病开放试验。

这些数字背后的记录
研究主题儿童影像与脑血流血管重建手术
论文中的科室神经外科儿科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肝豆状核变性

Wilson disease

2021–2025 年中国大陆作者发表的 201 篇肝豆状核变性 PubMed 英文论文中,这家医院牵头了 2 篇,占 1.0%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

长春有 1 家医院列在肝豆状核变性下全国有 28 家医院列在肝豆状核变性下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的肝豆状核变性开放试验。

这些数字背后的记录
研究主题遗传学(ATP7B)治疗(螯合剂、锌剂)诊断与铜代谢检测
论文中的科室消化/肝病科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

抗 NMDA 受体脑炎

Anti-NMDA receptor encephalitis

2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 5 篇,占 1.9%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 2220232024: 0020242025: 002025

长春有 1 家医院列在抗 NMDA 受体脑炎下全国有 124 家医院列在抗 NMDA 受体脑炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。

这些数字背后的记录
论文中的科室神经内科儿科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

大动脉炎

Takayasu arteritis

2021–2025 年中国大陆作者发表的 187 篇大动脉炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 1.1%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

长春有 3 家医院列在大动脉炎下全国有 100 家医院列在大动脉炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。

这些数字背后的记录
论文中的科室消化/肝病科临床试验/研究机构
牵头的论文2
  1. Exploring the causal relationship between Takayasu arteritis and inflammatory bowel disease using Mendelian randomization.2024Immunologic research
  2. AMPK hyperactivity maintains the survival of vasculogenic T cells in patients with Takayasu's arteritis.2023Clinical and experimental rheumatology
早期论文(2016–2020 年)1
  1. Ultrasound diagnosis and follow-up of Takayasu arteritis with femoral vein involvement.2019Journal of vascular surgery. Venous and lymphatic disorders
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis即将招募NCT07451665研究中心IV期2026-04 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

长春有 4 家医院列在特发性肺纤维化下全国有 288 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.3%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

长春有 3 家医院列在肌萎缩侧索硬化症下全国有 182 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

脊髓性肌萎缩症

Spinal muscular atrophy

2021–2025 年没有牵头脊髓性肌萎缩症的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

长春有 2 家医院列在脊髓性肌萎缩症下全国有 49 家医院列在脊髓性肌萎缩症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊髓性肌萎缩症开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Pediatric Spinal Muscular Atrophy (SMA) China Registry进行中,不再招募NCT05042921研究中心2021-11 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

法布雷病

Fabry disease

2021–2025 年中国大陆作者发表的 73 篇法布雷病 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

长春有 1 家医院列在法布雷病下全国有 80 家医院列在法布雷病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的法布雷病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

杜氏肌营养不良

Duchenne muscular dystrophy

2021–2025 年没有牵头杜氏肌营养不良的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

长春有 1 家医院列在杜氏肌营养不良下全国有 111 家医院列在杜氏肌营养不良下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.2%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 0020222023: 1120232024: 0020242025: 002025

长春有 4 家医院列在白塞病下全国有 139 家医院列在白塞病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。

这些数字背后的记录
论文中的科室影像/核医学科神经内科
牵头的论文3
  1. Recurrent aortic-arch pseudoaneurysm eroding into the left main bronchus following descending thoracic aortic stent repair.2023Journal of cardiothoracic surgery
  2. Long-segment diffuse cervical spinal cord involvement as the first episode of neuro-Behçet's disease: a case report.2021Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  3. Association between IL1B -511C/T polymorphism and Behçet's disease: a meta-analysis.2021The Journal of international medical research
早期论文(2016–2020 年)1
  1. Serum PLR and LMR in Behçet's disease: Can they show the disease activity?2017Medicine

打开 PubMed 检索ClinicalTrials.gov

其他疾病

Alport 综合征

Alport syndrome

2021–2025 年没有牵头Alport 综合征的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

长春有 2 家医院列在Alport 综合征下全国有 60 家医院列在Alport 综合征下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Alport 综合征开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 7 篇,占 0.9%。

牵头论文
7
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 3320222023: 0020232024: 1120242025: 112025

长春有 6 家医院列在IgA 肾病下全国有 300 家医院列在IgA 肾病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Nefecon and Ambrisentan in IgA Nephropathy
    分期
    IV期
    开始
    2025-09
    登记号
    NCT07030894

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:吉林大学第一医院长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室肾内科
牵头的论文7
  1. Inflammatory and nutritional indexes as predictors of acute kidney injury in patients with Immunoglobulin A nephropathy: a retrospective study.2025PeerJ
  2. Cathepsin S (CTSS) in IgA nephropathy: an exploratory study on its role as a potential diagnostic biomarker and therapeutic target.2024Frontiers in immunology
  3. Great prognosis of concurrent anti-GBM disease and IgA nephropathy in a young woman: A case report.2022Medicine
  4. Renal amyloidogenic leukocyte chemotactic factor 2 combined with IgA nephropathy: A case report.2022Medicine
  5. A noninvasive artificial neural network model to predict IgA nephropathy risk in Chinese population.2022Scientific reports
  6. Increased Tim-3+ monocytes/macrophages are associated with disease severity in patients with IgA nephropathy.2021International immunopharmacology
  7. Paraneoplastic immunoglobulin A nephropathy in a patient with lung adenocarcinoma: A case report and literature review.2021The Journal of international medical research
早期论文(2016–2020 年)6
  1. Increased Non-switched Memory B Cells are Associated with Plasmablasts, Serum IL-6 Levels and Renal Functional Impairments in IgAN Patients.2020Immunological investigations
  2. Identification of key genes, pathways and potential therapeutic agents for IgA nephropathy using an integrated bioinformatics analysis.2020Journal of the renin-angiotensin-aldosterone system : JRAAS
  3. Increased frequency of PD-1hiCXCR5- T cells and B cells in patients with newly diagnosed IgA nephropathy.2020Scientific reports
  4. Clinicopathologic correlations of renal biopsy findings from northeast China: A 10-year retrospective study.2019Medicine
  5. Efficacy and safety of mycophenolate mofetil in patients with IgA nephropathy: an update meta-analysis.2017BMC nephrology
  6. Serum Levels of Soluble ST2 and IL-10 Are Associated with Disease Severity in Patients with IgA Nephropathy.2016Journal of immunology research
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Nefecon and Ambrisentan in IgA Nephropathy正在招募NCT07030894牵头方IV期2025-09 启动
  2. A Study of Telitacicept for IgA Nephropathy (TELIGAN)进行中,不再招募NCT05799287研究中心III期2023-04 启动
  3. Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy状态不明NCT02231125研究中心IV期2014-09 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

戈谢病

Gaucher disease

2021–2025 年中国大陆作者发表的 30 篇戈谢病 PubMed 英文论文中,这家医院牵头了 1 篇,占 3.3%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

长春有 1 家医院列在戈谢病下全国有 40 家医院列在戈谢病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的戈谢病开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科
牵头的论文1
  1. Ambroxol Chaperone Therapy for Gaucher Disease Type I-Associated Liver Cirrhosis and Portal Hypertension: A Case Report.2022Endocrine, metabolic & immune disorders drug targets
早期论文(2016–2020 年)1
  1. [A case report of eight-year follow-up after splenectomy for Gaucher disease].2019Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology

打开 PubMed 检索ClinicalTrials.gov

其他疾病

成骨不全症

Osteogenesis imperfecta

2021–2025 年没有牵头成骨不全症的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

长春有 1 家医院列在成骨不全症下全国有 58 家医院列在成骨不全症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的成骨不全症开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta进行中,不再招募NCT05972551研究中心III期2024-04 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 11 篇,占 3.7%。

牵头论文
11
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 3320222023: 6620232024: 0020242025: 002025

长春有 4 家医院列在原发性胆汁性胆管炎下全国有 153 家医院列在原发性胆汁性胆管炎下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
    分期
    III期
    开始
    2025-12
    登记号
    NCT07282353

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 35 家列出的医院为研究中心上海、临沂、北京、十堰、南京、南宁、南昌、厦门、台州、合肥、哈尔滨、天津、宝鸡、成都、杭州、沈阳、深圳、湛江、福州、西安、郑州、重庆、长春、长沙、青岛

  2. 正在招募
    Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
    分期
    III期
    开始
    2023-09
    登记号
    NCT06051617

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、乌鲁木齐、北京、合肥、广州、成都、杭州、武汉、福州、西安、贵阳、郑州、重庆、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室消化/肝病科普外/肝胆胰外科
牵头的论文11
  1. The Albumin-Bilirubin Score as a Predictor of Liver-Related Mortality in Primary Biliary Cholangitis with Compensated Cirrhosis.2023Digestive diseases (Basel, Switzerland)
  2. Soluble immune checkpoints are elevated in patients with primary biliary cholangitis.2023European journal of medical research
  3. TR score: A noninvasive model to predict histological stages in patients with primary biliary cholangitis.2023Frontiers in immunology
  4. A large-scale plasma proteome Mendelian randomization study identifies novel causal plasma proteins related to primary biliary cholangitis.2023Frontiers in immunology
  5. The causal effects of inflammatory bowel disease on primary biliary cholangitis: A bidirectional two-sample Mendelian randomization study.2023Liver international : official journal of the International Association for the Study of the Liver
  6. FcγRIIB expression increases during primary biliary cholangitis.2023Molecular immunology
  7. The prognostic value of antibodies to gp210 among patients with primary biliary cholangitis in Northeast China.2022Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  8. Peroxisome Proliferator-Activated Receptors Regulate Hepatic Immunity and Assist in the Treatment of Primary Biliary Cholangitis.2022Frontiers in immunology
  9. Serum metabolic profiling of targeted bile acids reveals potentially novel biomarkers for primary biliary cholangitis and autoimmune hepatitis.2022World journal of gastroenterology
  10. Expanded circulating peripheral helper T cells in primary biliary cholangitis: Tph cells in PBC.2021Molecular immunology
  11. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome in a patient with paroxysmal nocturnal hemoglobinuria: a case report.2021The Journal of international medical research
早期论文(2016–2020 年)11
  1. Serotonin: A Potent Immune Cell Modulator in Autoimmune Diseases.2020Frontiers in immunology
  2. Total bile acid to platelet ratio: A noninvasive index for predicting liver fibrosis in primary biliary cholangitis.2020MedicineRCT
  3. Clinical significance of IgG antimitochondrial M2 antibody levels in primary biliary cholangitis: A single center study from China.2020PloS one
  4. The Potential Effects of Diabetes Mellitus on Liver Fibrosis in Patients with Primary Biliary Cholangitis.2019Medical science monitor : international medical journal of experimental and clinical research
  5. Primary biliary cholangitis is more severe in previous hepatitis B virus infection patients.2018European journal of gastroenterology & hepatology
  6. Primary biliary cirrhosis with refractory hypokalemia: A case report.2018Medicine
  7. Median arcuate ligament syndrome and arterial anastomotic bleeding inducing hepatic artery thrombosis after liver transplantation: A case report.2018Medicine
  8. Primary cutaneous amyloidosis associated with autoimmune hepatitis-primary biliary cirrhosis overlap syndrome and Sjögren syndrome: A case report.2018Medicine
  9. Platelet count to spleen thickness ratio is related to histologic severity of primary biliary cholangitis.2018Medicine
  10. Red blood cell distribution width and globulin, noninvasive indicators of fibrosis and inflammation in chronic hepatitis patients.2016European journal of gastroenterology & hepatology
  11. [Association between chronic urinary tract infection and primary biliary cirrhosis].2016Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
它在 ClinicalTrials.gov 上的全部试验(任何状态)7
  1. A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA正在招募NCT07282353研究中心III期2025-12 启动
  2. Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis正在招募NCT06051617研究中心III期2023-09 启动
  3. CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)进行中,不再招募NCT05896124研究中心II期2023-08 启动
  4. Study of Obeticholic Acid(OCA) Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primay Biliary Cirrhosis (PBC)状态不明NCT04956328研究中心III期2021-07 启动
  5. Obeticholic Acid Versus Placebo, in Combination with Ursodeoxycholic Acid in Patients with Primary Biliary Cirrhosis已完成NCT06715319研究中心III期2021-10 启动
  6. A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis进行中,不再招募NCT05050136研究中心II期2021-09 启动
  7. A Study of TQA3526 in the Treatment of Primary Biliary Cirrhosis (PBC)状态不明NCT04278820研究中心II期2020-03 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性硬化性胆管炎

Primary sclerosing cholangitis

2021–2025 年中国大陆作者发表的 100 篇原发性硬化性胆管炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.0%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

长春有 2 家医院列在原发性硬化性胆管炎下全国有 89 家医院列在原发性硬化性胆管炎下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
    分期
    III期
    开始
    2026-05
    登记号
    NCT07387549

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、南昌、天津、广州、济南、郑州、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室普外/肝胆胰外科
牵头的论文1
  1. Proteome-wide Mendelian randomization highlights AIF1 and HLA-DQA2 as targets for primary sclerosing cholangitis.2024Hepatology international
早期论文(2016–2020 年)2
  1. IgG4-related sclerosing cholangitis and chronic sclerosing sialadenitis mimicking cholangiocarcinoma and neck malignancy.2017Hepatobiliary & pancreatic diseases international : HBPD INT
  2. IgG4-related sclerosing cholangitis overlapping with autoimmune hepatitis: Report of a case.2017Pathology, research and practice
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis正在招募NCT07387549研究中心III期2026-05 启动
  2. CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis)进行中,不再招募NCT05896137研究中心II期2023-08 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

家族性腺瘤性息肉病

Familial adenomatous polyposis

2021–2025 年没有牵头家族性腺瘤性息肉病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

长春有 1 家医院列在家族性腺瘤性息肉病下全国有 74 家医院列在家族性腺瘤性息肉病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。

这些数字背后的记录
论文中的科室消化/肝病科
中文论文(未计入)1
  1. [Advance in genetics research on Gastrointestinal polyposis syndromes].2025Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics

打开 PubMed 检索ClinicalTrials.gov

其他相关研究

联系这家医院

出示给工作人员或司机的院名卡

吉林大学第一医院

First Hospital of Jilin University

长春

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请以上方链接的医院官方页面为准。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
First Bethune Hospital of Jilin University; First Bethune Hospital; Jilin University First Hospital; Cancer Center of the First Hospital of Jilin University; First Hospital of Jilin University Cancer Center; Orthopedics Center The First Hospital of Jilin University; First Hospital of jilin University; General Surgery Center of the First Hospital of Jilin University

提出更正下载数据